The short-term progression of asymptomatic chronic hepatitis C patients with mild fibrosis is excellent. Non-invasive test is easy and use to monitor the progression of fibrosis. Interferon regimen is the treatment for HCV patients, currently direct-acting antiviral drug (DDA) regimens is more effective and shorter duration. Many DDA regimens can have sustained viral response (SVR) rates of more than 90% and safety outcomes. Furthermore, all-oral interferon free regimens are not cost-effective for patients with mild fibrosis disease. The HCV treatment should be deferred for a few years and the progression of fibrosis is regularly monitored. This option is safe until new treatment, which is cheaper, shorter, more effective and more convenient, become available.

